搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
2 天
FDA approves Humacyte’s off-the-shelf artery implant for vascular trauma repair
The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...
FierceBiotech
2 天
Fierce Biotech's top 10 editor's picks for 2024
The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...
FierceBiotech
2 天
Editor’s corner: Fierce Medtech’s top 10 stories of 2024 chart the industry’s highs ...
A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations. | A ...
FierceBiotech
2 天
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis ...
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...
FierceBiotech
2 天
Phase 2 data will drive biopharma VC investments next year: PitchBook
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...
FierceBiotech
2 天
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...
FierceBiotech
5 天
Sanofi scoops up China rights to Cytokinetics' heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
FierceBiotech
5 天
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
FierceBiotech
2 天
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
FierceBiotech
4 天
Galectin's MASH treatment reduces varices but fails to hit statistical significance in ...
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...
FierceBiotech
2 天
Editor's Corner: Fierce Biotech's 10 most-read stories of 2024
Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. | For the end of this year, ...
FierceBiotech
5 天
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor ...
After learning of the warning letter, an investor accused Applied of knowing about these trial issues but not disclosing them ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈